Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Cancer Research Society Doctoral Research Awards - ICR-ISI

University of British Columbia

$35,000.00

Investigating the T cell response against the oncomicrobe Fusobacterium nucleatum to inform vaccine development

FY 2026-27

Summary
Fusobacterium nucleatum (Fn) was identified to be enriched (PMID 22009989) and is now a well-characterized oncomicrobe in colorectal cancer (CRC) (PMID 34490259). Fn is highly prevalent in CRC and its presence in tumors is not a rare occurrence (PMID 39930345). Fn localizes to tumors haematogenously (PMID 32850497) and colonizes where it promotes tumor progression and metastasis, as well as confers resistance to chemotherapy and immunotherapy (PMID 38289287). Furthermore, Fn abundance in patient tumors tracks with tumor development from early-stage lesions to late-stage invasive carcinomas (PMID 24599709). Therefore, there is a need to test whether selectively blocking Fn tumor colonization prevents the associated poor patient outcomes. Our research goal is to develop an Fn vaccine that can confer complete, selective protection against Fn tumor colonization that can in turn provide clinical benefit to patients in an adjuvant setting or patients at risk of CRC development or recurrence.
Program
Cancer Research Society Doctoral Research Awards - ICR-ISI
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
580348
Name
Lee Tracy S
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Investigating the T cell response against the oncomicrobe Fusobacterium nucleatum to inform vaccine development
Programtype2
Miscellaneous Programs
Orgnameinp2
University of British Columbia
Cihramount2
$35,000
Cihrequipment2
$0
Programname2
Cancer Research Society Doctoral Research Awards - ICR-ISI
Keyworddelim
Cancer
Abstract
Fusobacterium nucleatum (Fn) was identified to be enriched (PMID 22009989) and is now a well-characterized oncomicrobe in colorectal cancer (CRC) (PMID 34490259). Fn is highly prevalent in CRC and its presence in tumors is not a rare occurrence (PMID 39930345). Fn localizes to tumors haematogenously (PMID 32850497) and colonizes where it promotes tumor progression and metastasis, as well as confers resistance to chemotherapy and immunotherapy (PMID 38289287). Furthermore, Fn abundance in patient tumors tracks with tumor development from early-stage lesions to late-stage invasive carcinomas (PMID 24599709). Therefore, there is a need to test whether selectively blocking Fn tumor colonization prevents the associated poor patient outcomes. Our research goal is to develop an Fn vaccine that can confer complete, selective protection against Fn tumor colonization that can in turn provide clinical benefit to patients in an adjuvant setting or patients at risk of CRC development or recurrence.
Competitiondate
202604
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lee, Tracy S
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $35,000~ $0~